

## Northern (NHS) Treatment Advisory Group

### Treatment Appraisal: Decision Summary

|                                    |  |
|------------------------------------|--|
| Date                               | 25 <sup>th</sup> February 2014   |
| Appraisal                          | Nalmefene (Selincro®) in the management of alcohol dependence  |
| Details                            | The Northern (NHS) Treatment Advisory Group considered an appraisal of nalmefene (Selincro®, Lundbeck) for use in accordance within its licensed indication in the management of alcohol dependence.   |
| Recommendation                     | <p><b>The Northern (NHS) Treatment Advisory Group does not recommend nalmefene (Selincro®) in the management of alcohol dependence.</b></p> <p>The group was concerned with the quality and generalisability of the clinical evidence, and limitations around the practical introduction of the treatment into current practice and services.</p>  |
| Clinical evidence summary          | <p>The group considered the clinical evidence supporting the licensed nalmefene product, both the whole and licensed study populations, and was concerned about the methodological processes and clinical relevance of the outcomes.</p> <p>In addition, the group was concerned that existing local practice and services were not amenable to the introduction of nalmefene with the associated package of care which would be required.</p> <p>The group felt that the net population impact of nalmefene would be very limited due to its likely niche use in a specific and small patient population.</p> |
| Cost analysis summary              | The group noted that the cost of treatment would vary depending on how frequently the treatment was used by individual patients, and by the total duration of treatment. Nonetheless, annual treatment costs were estimated at between £400 and £600 per patient, which was at the upper end of the range of other drugs used in the management of alcohol dependence.   |
| Financial impact<br>PbR: In-tariff | The group considered that the net financial impact from the introduction of nalmefene used within the requirements of its product license would potentially be limited due to its likely niche target population.  |
| Further research or information    | The group recognised that NICE is currently undertaking an appraisal of nalmefene for reducing alcohol consumption in people with alcohol dependence and is due to publish its recommendation in November 2014.  |

Not to be used for commercial or marketing purposes